Revision of OTC antihistamine final monograph may be necessary -- FDA's Weintraub.
This article was originally published in The Tan Sheet
Executive Summary
OTC ANTIHISTAMINE FINAL MONOGRAPH WOULD HAVE TO BE REVISED if FDA decides to require clinical studies to support a cold indication for every Category I antihistamine ingredient, FDA Office of Drug Evaluation V Director Michael Weintraub, MD, stated at the Nov. 16 meeting of the Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees in Rockville.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: